Article
Medicine, Research & Experimental
Bryan Li, Thomas Yau, Roland Leung, Gerry Kwok, Josephine Tsang, Polly Cheung, T. T. Wong, Dacita Suen, Ava Kwong, Joanne W. Chiu
Summary: Concurrent anthracycline and taxane is effective for neoadjuvant chemotherapy in HER2-negative breast cancers. 6 cycles of TEC with prophylactic G-CSF is well tolerated, with hematological toxicities being the most common adverse effects.
ADVANCES IN THERAPY
(2021)
Article
Oncology
Rupert Bartsch, Christian F. Singer, Georg Pfeiler, Michael Hubalek, Herbert Stoeger, Angelika Pichler, Edgar Petru, Vesna Bjelic-Radisic, Richard Greil, Margaretha Rudas, Tea Maria Muy-Kheng, Viktor Wette, Andreas L. Petzer, Paul Sevelda, Daniel Egle, Peter C. Dubsky, Martin Filipits, Florian Fitzal, Ruth Exner, Raimund Jakesz, Marija Balic, Christoph Tinchon, Zsuzsanna Bago-Horvath, Sophie Frantal, Michael Gnant
Summary: The study compared two different anthracycline/taxane sequences in HER2-negative early-stage breast cancer patients and found no significant differences in treatment outcomes between conventional and reverse chemotherapy sequences. Upfront docetaxel did not improve chemotherapy activity or tolerability, suggesting that upfront neoadjuvant treatment with anthracyclines remains a valid option.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Wei Wu, Jiewen Chen, Heran Deng, Liang Jin, Zhanghai He, Nanyan Rao, Yan Nie, Yandan Yao, Yaping Yang, Fengxi Su, Jieqiong Liu
Summary: In this study, neoadjuvant treatment with everolimus plus letrozole showed promising results in improving ultrasound response rate with lower toxicities for postmenopausal patients with ER-positive, HER2-negative breast cancer. The treatment also demonstrated positive antitumoral immunity effects, which warrants further large randomized controlled trials for validation.
Article
Oncology
Xian Wu, Chaoran Ye, Xingmeng Wang, Ruyu Cai, Junzhe Yang, Xiafei Yu, Yi Zhou, Li Shen, Yanhui Zhu, Xiaoan Liu
Summary: This study retrospectively analyzed the efficacy and toxicity of epirubicin plus cyclophosphamide followed by docetaxel (EC-D) and epirubicin plus cyclophosphamide followed by paclitaxel (EC-P) as neoadjuvant chemotherapy regimens. The results showed that the rate of pathological complete response (pCR) was higher in EC-P compared to EC-D. Patients with ER (-), PR (-), Her-2 (+), and high Ki-67 index were more likely to achieve pCR with EC-P.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Kerstin Wimmer, Monika Sachet, Cristiano Ramos, Sophie Frantal, Hanna Birnleitner, Christine Brostjan, Ruth Exner, Martin Filipits, Zsuzsanna Bago-Horvath, Margaretha Rudas, Rupert Bartsch, Michael Gnant, Christian F. Singer, Marija Balic, Daniel Egle, Rudolf Oehler, Florian Fitzal
Summary: This study compared the immunomodulatory effects of Epirubicin/cyclophosphamide (EC) and docetaxel (D) in neoadjuvant treatment of breast cancer. The results showed that EC had strong immunosuppressive properties, while D had a supportive effect on the immune system. These findings have important implications for the planning of combination therapies with immunotherapies in breast cancer.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Deyue Liu, Jiayi Wu, Caijin Lin, Shuning Ding, Shuangshuang Lu, Yan Fang, Jiahui Huang, Jin Hong, Weiqi Gao, Siji Zhu, Xiaosong Chen, Ou Huang, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen, Li Zhu
Summary: Anthracycline and taxane-based chemotherapy are commonly used adjuvant therapy for early breast cancer. Removing anthracycline from the treatment regimen is a feasible alternative for HER2-negative breast cancer patients. The ELEGANT trial compared the safety and efficacy of epirubicin and cyclophosphamide (EC) versus docetaxel and cyclophosphamide (TC) and found that the rate of grade 3 or 4 neutropenia is similar between the two regimens, but more adverse events were observed in the EC group.
Article
Oncology
Yin Liu, Lei Fan, Zhong-Hua Wang, Zhi-Ming Shao
Summary: This study evaluated the efficacy and safety of nab-paclitaxel followed by dose-dense epirubicin/cyclophosphamide as neoadjuvant therapy in patients with triple-negative breast cancer, showing promising anti-tumor activity and acceptable tolerability.
Article
Oncology
George Douganiotis, Savvas Grigoriadis, Loukas Kontovinis, Efrosini Markopoulou, Athanasios Pouptsis, Konstantinos Papazisis
Summary: In early HER2-positive breast cancer, neoadjuvant chemotherapy with a combination of epirubicin, cyclophosphamide, docetaxel, trastuzumab, and pertuzumab showed high effectiveness with minimal cardiac side effects. Among 55 patients treated with this regimen, 64.8% achieved complete pathologic response, and only one recorded asymptomatic LVEF fall > 25% during a median 2.61-year cardiac follow-up.
Article
Oncology
Mads H. Haugen, Ole Christian Lingjaerde, Ingrid Hedenfalk, Oystein Garred, Elin Borgen, Niklas Loman, Thomas Hatschek, Anne-Lise Borresen-Dale, Bjorn Naume, Gordon B. Mills, Gunhild M. Maelandsmo, Olav Engebraaten
Summary: In breast cancer patients, a nine-protein signature score named vascular endothelial growth factor inhibition response predictor (ViRP) was identified to predict the effectiveness of treatment with bevacizumab combined with chemotherapy, based on the expression levels of selected proteins. This ViRP score was internally validated on mRNA data and also validated in an independent phase II clinical trial, showing promise in predicting treatment benefit in HER2-negative breast cancer patients.
JCO PRECISION ONCOLOGY
(2021)
Article
Oncology
Liulu Zhang, Zhi-Yong Wu, Jie Li, Ying Lin, Zhenzhen Liu, Yin Cao, Gangling Zhang, Hong-Fei Gao, Mei Yang, Ci-Qiu Yang, Teng Zhu, Min-Yi Cheng, Fei Ji, Jieqing Li, Kun Wang
Summary: In a randomized controlled trial, it was found that the addition of carboplatin to neoadjuvant chemotherapy significantly improved the pathologic complete response rate in patients with untreated stage II-III TNBC compared to anthracycline-based regimens. Despite the different treatment protocols, overall survival and event-free survival rates were comparable between the two groups after a 37-month follow-up period.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Houpu Yang, Ling Xu, Shan Guan, Xiaopeng Hao, Zhicheng Ge, Fuzhong Tong, Yingming Cao, Peng Liu, Bo Zhou, Lin Cheng, Miao Liu, Hongjun Liu, Fei Xie, Siyuan Wang, Yuan Peng, Chaobin Wang, Shu Wang
Summary: This study evaluated the efficacy and safety of the combination of docetaxel and capecitabine in the treatment of early breast cancer and compared it with the combination of docetaxel and epirubicin. The results showed comparable rates of pathological complete response and long-term survival between the two treatment regimens, suggesting that the anthracycline-free TX regimen could be considered in selected patients.
Article
Oncology
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Summary: In this study, nab-PTX plus trastuzumab and pertuzumab showed a high pCR rate in HER2-positive breast cancer, especially in the HER2 subtype. Although there were some adverse events, they were generally acceptable, indicating that this regimen is safe and effective as neoadjuvant chemotherapy for HER2-positive breast cancer.
Article
Oncology
Jiahui Huang, Yiwei Tong, Jin Hong, Ou Huang, Jiayi Wu, Jianrong He, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen
Summary: This study aimed to evaluate the efficacy, safety, and metabolic parameters change of metformin combined with TEC in neoadjuvant treatment for breast cancer patients with metabolic abnormality. The results showed that adding metformin did not increase the total pathological complete response rate and disease outcome in breast cancer patients, but it could prevent the increase of total cholesterol and low-density lipoprotein cholesterol after treatment.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Akiko Matsumoto, Hiromitsu Jinno, Saki Naruse, Yuka Isono, Yuka Maeda, Ayana Sato, Miki Yamada, Tatsuhiko Ikeda, Yuko Sasajima
Summary: This study evaluated the efficacy and safety of dose-dense nanoparticle albumin-bound paclitaxel followed by dose-dense epirubicin and cyclophosphamide as neoadjuvant chemotherapy for HER2-negative operable breast cancer. The results showed that this treatment was effective, especially for patients with triple-negative disease, and feasible with pegfilgrastim support.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Jiong Wu, Zefei Jiang, Zhenzhen Liu, Benlong Yang, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Xiaoyu Zhu, Fei Wu, Xiang Lin, Jianjun Zou
Summary: This study demonstrates that neoadjuvant pyrotinib, trastuzumab, and docetaxel significantly improve the total pathological complete response rate compared to placebo, trastuzumab, and docetaxel in patients with HER2-positive early or locally advanced breast cancer, with manageable toxicity. This provides a new option for the treatment of HER2-positive breast cancer.
Article
Oncology
Tamas Hickish, Ajay Mehta, Mei-Ching Liu, Chiun-Sheng Huang, Rajendra Singh Arora, Yuan-Ching Chang, Youngsen Yang, Vladimir Vladimirov, Minish Jain, Janice Tsang, Karine Pemberton, Behbood Sadrolhefazi, Xidong Jin, Ling-Ming Tseng
Summary: This study investigated the efficacy and safety of using the irreversible ErbB family blocker, afatinib, as first-line therapy for metastatic breast cancer patients who had failed prior HER2-targeted therapy. Results showed that afatinib treatment, alone or in combination with vinorelbine or paclitaxel, had a positive effect on a significant number of patients. Treatment-related adverse events were generally manageable, with no significant increase in toxicity observed.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Editorial Material
Medicine, General & Internal
Charlotte Elizabeth Coles, Benjamin O. Anderson, David Cameron, Fatima Cardoso, Richard Horton, Felicia Marie Knaul, Miriam Mutebi, Naomi Lee
Article
Oncology
Christina Yau, Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze, Anne-Sophie Harny, Marick Lae, Fabien Reyal, Gabes S. Sonke, Tessa G. Steenbruggen, Maartje van Seijen, Jelle Wesseling, Miguel Martin, Maria del Monte-Millan, Sara Lopez-Tarruella, Judy C. Boughey, Matthew P. Goetz, Tanya Hoskin, Rebekah Gould, Vicente Valero, Stephen B. Edge, Jean E. Abraham, John M. S. Bartlett, Carlos Caldas, Janet Dunn, Helena Earl, Larry Hayward, Louise Hiller, Elena Provenzano, Stephen-John Sammut, Jeremy S. Thomas, David Cameron, Ashley Graham, Peter Hail, Lorna Mackintosh, Fang Fan, Andrew K. Godwin, Kelsey Schwensen, Priyanko Sharma, Angela M. DeMichele, Kimberly Cole, Lajos Pusztai, Mi-Ok Kim, Laura J. van't Veer, Laura J. Esserman, W. Fraser Symmans
Summary: This study analyzed data from multiple independent cohorts to evaluate the relationship between residual cancer burden (RCB) and long-term prognosis in different subtypes of breast cancer. The results showed that higher RCB score was significantly associated with worse event-free survival in all breast cancer subtypes. The study suggests considering the evaluation of RCB as part of standard pathology reporting.
Article
Oncology
Lorenzo Gerratana, Jean-Yves Pierga, James M. Reuben, Andrew A. Davis, Firas H. Wehbe, Luc Dirix, Tanja Fehm, Franco Nole, Rafael Gisbert-Criado, Dimitrios Mavroudis, Salvatore Grisanti, Jose A. Garcia-Saenz, Justin Stebbing, Carlos Caldas, Paola Gazzaniga, Luis Manso, Rita Zamarchi, Marta Bonotto, Angela Fernandez de Lascoiti, Leticia De Mattos-Arruda, Michail Ignatiadis, Maria-Teresa Sandri, Daniele Generali, Carmine De Angelis, Sarah-Jane Dawson, Wolfgang Janni, Vicente Caranana, Sabine Riethdorf, Erich-Franz Solomayer, Fabio Puglisi, Mario Giuliano, Klaus Pantel, Francois-Clement Bidard, Massimo Cristofanilli
Summary: This study developed a classifier for prognostic simulation of circulating tumor cells (CTCs) in metastatic breast cancer (MBC) patients. The classifier accurately predicted patients' prognosis and stratified them into different clinical subgroups. It also revealed differential prognostic impact of endocrine therapy (ET) and chemotherapy (CT) in different subgroups.
Article
Cell Biology
Nishanth Belugali Nataraj, Ashish Noronha, Joo Sang Lee, Soma Ghosh, Harsha Raj Mohan Raju, Arunachalam Sekar, Binyamin Zuckerman, Moshit Lindzen, Emilio Tarcitano, Swati Srivastava, Michael Selitrennik, Ido Livneh, Diana Drago-Garcia, Oscar Rueda, Carlos Caldas, Sima Lev, Tamar Geiger, Aaron Ciechanover, Igor Ulitsky, Rony Seger, Eytan Ruppin, Yosef Yarden
Summary: By establishing multi-omics pipelines, we discovered that overexpression of NUP93 is associated with aggressive human mammary tumors, enhancing their migration and invasion capabilities. NUP93 is involved in nuclear transport, activating various signaling pathways and ultimately contributing to tumor growth and metastasis. Targeting this nuclear transport process with myristoylated peptides can inhibit tumor growth and metastasis.
Article
Oncology
Tom van den Bosch, Oscar M. Rueda, Carlos Caldas, Louis Vermeulen, Daniel M. Miedema
Summary: This study found that low-risk breast cancer patients identified using chromosomal copy-number ITH do not benefit from adjuvant endocrine therapy.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Xiaoyu Wang, Puya Gharahkhani, David M. Levine, Rebecca C. Fitzgerald, Ines Gockel, Douglas A. Corley, Harvey A. Risch, Leslie Bernstein, Wong-Ho Chow, Lynn Onstad, Nicholas J. Shaheen, Jesper Lagergren, Laura J. Hardie, Anna H. Wu, Paul D. P. Pharoah, Geoffrey Liu, Lesley A. Anderson, Prasad G. Iyer, Marilie D. Gammon, Carlos Caldas, Weimin Ye, Hugh Barr, Paul Moayyedi, Rebecca Harrison, R. G. Peter Watson, Stephen Attwood, Laura Chegwidden, Sharon B. Love, David MacDonald, John DeCaestecker, Hans Prenen, Katja Ott, Susanne Moebus, Marino Venerito, Hauke Lang, Rupert Mayershofer, Michael Knapp, Lothar Veits, Christian Gerges, Josef Weismueller, Matthias Reeh, Markus M. Noethen, Jakob R. Izbicki, Hendrik Manner, Horst Neuhaus, Thomas Roesch, Anne C. Boehmer, Arnulf H. Hoelscher, Mario Anders, Oliver Pech, Brigitte Schumacher, Claudia Schmidt, Thomas Schmidt, Tania Noder, Dietmar Lorenz, Michael Vieth, Andrea May, Timo Hess, Nicole Kreuser, Jessica Becker, Christian Ell, Ian Tomlinson, Claire Palles, Janusz A. Jankowski, David C. Whiteman, Stuart MacGregor, Johannes Schumacher, Thomas L. Vaughan, Matthew F. Buas, James Y. Dai
Summary: This study identified novel genetic susceptibility loci for esophageal adenocarcinoma and Barrett esophagus using an eQTL set-based genetic association approach, expanding the pool of genetic susceptibility loci.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
C. E. Geyer, J. E. Garber, R. D. Gelber, G. Yothers, M. Taboada, L. Ross, P. Rastogi, K. Cui, A. Arahmani, G. Aktan, A. C. Armstrong, M. Arnedos, J. Balmana, J. Bergh, J. Bliss, S. Delaloge, S. M. Domchek, A. Eisen, F. Elsafy, L. E. Fein, A. Fielding, J. M. Ford, S. Friedman, K. A. Gelmon, L. Gianni, M. Gnant, S. J. Hollingsworth, S-A Im, A. Jager, S. R. Lakhani, W. Janni, B. Linderholm, T-W Liu, N. Loman, L. Korde, S. Loibl, P. C. Lucas, F. Marme, E. Martinez de Duenas, R. McConnell, K-A Phillips, M. Piccart, G. Rossi, R. Schmutzler, E. Senkus, Z. Shao, P. Sharma, C. F. Singer, T. Spanic, E. Stickeler, M. Toi, T. A. Traina, G. Viale, G. Zoppoli, Y. H. Park, R. Yerushalmi, H. Yang, D. Pang, K. H. Jung, A. Mailliez, Z. Fan, I Tennevet, J. Zhang, T. Nagy, G. S. Sonke, Q. Sun, M. Parton, M. A. Colleoni, M. Schmidt, A. M. Brufsky, W. Razaq, B. Kaufman, D. Cameron, C. Campbell, A. N. J. Tutt, O. Th Johannsson
Summary: The OlympiA trial demonstrated that adjuvant therapy with the oral PARP inhibitor, olaparib, significantly improves overall survival in patients with gBRCA1/2pv-associated early breast cancer. The study also showed improvements in invasive disease-free survival and distant disease-free survival, with no new safety issues identified.
ANNALS OF ONCOLOGY
(2022)
Article
Genetics & Heredity
Sue Philpott, Maria Raikou, Ranjit Manchanda, Michelle Lockley, Naveena Singh, Malcolm Scott, D. Gareth Evans, Julian Adlard, Munaza Ahmed, Richard Edmondson, Emma Roisin Woodward, Athena Lamnisos, Janos Balega, Angela F. Brady, Aarti Sharma, Louise Izatt, Anjana Kulkarni, Vishakha Tripathi, Joyce S. Solomons, Kevin Hayes, Helen Hanson, Katie Snape, Lucy Side, Steve Skates, Alistair McGuire, Adam N. Rosenthal
Summary: This study aimed to evaluate the effectiveness and cost-effectiveness of ovarian cancer surveillance in BRCA1/2-heterozygous women deferring risk-reducing surgery. The results showed that surveillance in a real-world setting was feasible and demonstrated similar performance to research trials, effectively down-staging ovarian cancer and saving costs.
JOURNAL OF MEDICAL GENETICS
(2023)
Article
Oncology
N. C. Turner, C. Swift, B. Jenkins, L. Kilburn, M. Coakley, M. Beaney, L. Fox, K. Goddard, I. Garcia-Murillas, P. Proszek, P. Hall, C. Harper-Wynne, T. Hickish, S. Kernaghan, I. R. Macpherson, A. F. C. Okines, C. Palmieri, S. Perry, K. Randle, C. Snowdon, H. Stobart, A. M. Wardley, D. Wheatley, S. Waters, M. C. Winter, M. Hubank, S. D. Allen, J. M. Bliss
Summary: The c-TRAK TN study is the first prospective study to evaluate the clinical utility of ctDNA testing in guiding therapy in TNBC. It found that TNBC patients had a high rate of metastatic disease on ctDNA detection. These findings have important implications for future trial design, emphasizing the importance of starting ctDNA testing early and using more sensitive and/or frequent ctDNA testing regimes.
ANNALS OF ONCOLOGY
(2023)
Article
Mathematical & Computational Biology
Pavel Mozgunov, Thomas Jaki, Ioannis Gounaris, Thomas Goddemeier, Anja Victor, Marianna Grinberg
Summary: There is a growing medical interest in combining multiple drugs and optimizing dosing schedules in a single trial, but there are challenges in implementing advanced statistical methods. By sharing the experience of implementing a model-based partial ordering continual reassessment method (POCRM) design, the hope is to facilitate the uptake of more efficient methods in practice.
STATISTICS IN MEDICINE
(2022)
Article
Multidisciplinary Sciences
Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens, Samuel Aparicio, Ayse Bassez, Ake Borg, Jane Brock, Annegien Broeks, Carlos Caldas, Fatima Cardoso, Maxim De Schepper, Mauro Delorenzi, Caroline A. Drukker, Annuska M. Glas, Andrew R. Green, Edoardo Isnaldi, Jorunn Eyfjoro, Hazem Khout, Stian Knappskog, Savitri Krishnamurthy, Sunil R. Lakhani, Anita Langerod, John W. M. Martens, Amy E. McCart Reed, Leigh Murphy, Stefan Naulaerts, Serena Nik-Zainal, Ines Nevelsteen, Patrick Neven, Martine Piccart, Coralie Poncet, Kevin Punie, Colin Purdie, Emad A. Rakha, Andrea Richardson, Emiel Rutgers, Anne Vincent-Salomon, Peter T. Simpson, Marjanka K. Schmidt, Christos Sotiriou, Paul N. Span, Kiat Tee Benita Tan, Alastair Thompson, Stefania Tommasi, Karen Van Baelen, Marc Van de Vijver, Steven Van Laere, Laura van't Veer, Giuseppe Viale, Alain Viari, Hanne Vos, Anke T. Witteveen, Hans Wildiers, Giuseppe Floris, Abhishek D. Garg, Ann Smeets, Diether Lambrechts, Elia Biganzoli, Francois Richard, Christine Desmedt
Summary: Obesity is associated with an increased risk of developing breast cancer and worse prognosis in breast cancer patients. This study investigates the biological differences in untreated primary breast cancer according to patients' body mass index (BMI). The study finds several genomic alterations that are differentially prevalent in overweight or obese patients compared to lean patients. It also reveals an elevated and unresolved inflammation of the breast cancer tumor microenvironment associated with obesity. The findings suggest that patient adiposity may play a significant role in the heterogeneity of breast cancer and should be considered for tailored treatment.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Edwin Cuppen, Olivier Elemento, Richard Rosenquist, Svetlana Nikic, Maarten IJzerman, Isabelle Durand Zaleski, Geert Frederix, Lars-Ake Levin, Charles G. Mullighan, Reinhard Buettner, Trevor J. Pugh, Sean Grimmond, Carlos Caldas, Fabrice Andre, Ilse Custers, Elias Campo, Hans van Snellenberg, Anna Schuh, Hidewaki Nakagawa, Christof von Kalle, Torsten Haferlach, Stefan Froehling, Vaidehi Jobanputra
Summary: The combination of whole-genome and transcriptome sequencing (WGTS) is a comprehensive precision diagnostic test that is expected to transform diagnosis and treatment for cancer patients. However, there are barriers to the implementation and widespread adoption of this test, including considerations of utility in different cancer types, cost-effectiveness and affordability.
JCO PRECISION ONCOLOGY
(2022)
Review
Oncology
Emily A. Kolyvas, Carlos Caldas, Kathleen Kelly, Saif S. Ahmad
Summary: Breast cancer is a common and deadly cancer, and the role of AR in this type of cancer is still not fully understood. However, targeting AR in breast cancer may have therapeutic potential and further research is needed for effective treatment.
BREAST CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Stephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin, Elena Provenzano, Helen A. Bardwell, Wenxin Ma, Wei Cope, Ali Dariush, Sarah-Jane Dawson, Jean E. Abraham, Janet Dunn, Louise Hiller, Jeremy Thomas, David A. Cameron, John M. S. Bartlett, Larry Hayward, Paul D. Pharoah, Florian Markowetz, Oscar M. Rueda, Helena M. Earl, Carlos Caldas
Summary: The response to therapy in breast cancers is influenced by the pre-treated tumour ecosystem, and predictive models integrating multi-omics features through machine learning can be used to predict treatment outcomes. The degree of residual disease following therapy is monotonically associated with pre-therapy features of the tumour.